Navigation Links
Concord Medical Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting, Board and Management Changes
Date:12/2/2011

re, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Such factors include the number of new radiotherapy and diagnostic imaging centers opened; the increase in the number of patients in existing centers; the establishment of specialty cancer hospitals; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the PRC government; technological or therapeutic changes affecting the field of cancer treatment and diagnostic imaging; and possible effects on consumers and hospitals, hospital construction, and suppliers, as a result of inflation and the Chinese government's policies and actions to control inflation. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov. The Company does not assume any obligation to update any forward-looking statement, except as required by law.For more information, please contact:Concord Medical ServicesMr. Tony Tian (Chinese and English)+86 10 5957 5287tony.tian@concordmedical.com ChristensenMs. Teal Willingham (English and Chinese)+86 131 2179 3446twillingham@christensenir.com Ms. Kimberly Minarovich (English)+1 212 618 1978kminarovich@christensenir.com ir.concordmedical.com
'/>"/>
SOURCE Concord Medical Services Holdings Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. New Study Shows Concord Grape Juice has a Heart-Healthy Effect not yet Reported With Red Wine
2. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
3. Concord Grape Juice Has No Significant Impact on Body Weight
4. Concord Medical to Report First Quarter 2010 Financial Results on Thursday, May 27, 2010
5. Concord Medical Announces New Centers Opening at Hospital Partner
6. Concord Medical Announces Share Repurchase Program
7. Concord Medical Files 2009 Annual Report on Form 20-F
8. Concord Medical Enters into Joint Venture Agreement with ChangAn Hospital
9. Concord Medical to Report Second Quarter 2010 Financial Results on Wednesday, August 18, 2010
10. Concord Medical Announces Second Quarter 2010 Financial Results
11. Concord Medical to Hold Annual General Meeting on December 11, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, ... PTN), a biopharmaceutical company developing targeted, receptor-specific peptide ... unmet medical need and commercial potential, today announced ... of 2,050,000 shares of its common stock and ... its common stock.  Funds under the management of ...
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... decision support to healthcare providers for behavioral health ... has secured $30 million in equity financing from ... C. Drosos , President and Chief Executive Officer. ... adoption and development of Assurex Health,s GeneSight ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... MITI ), a biopharmaceutical company developing novel, ... autoimmune,diseases, announced the start of a phase 1 ... will explore the safety, pharmacokinetics,pharmacodynamics and anti-tumor activity ... MT110 targets the epithelial cell adhesion molecule ...
... an oncolytic product, WOBURN, Mass., April 22 ... treatments for cancer and the prevention,of infectious disease, ... (FDA) has approved the design of a single, ... OncoVEX(GM-CSF) in,previously treated patients with metastatic melanoma. The ...
Cached Medicine Technology:Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 2Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 3Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 4Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors 5BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO 2BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO 3
(Date:12/25/2014)... 2014 Recently, BellasDress has ... its wedding dresses. BellasDress has chosen their best-selling lace ... choices for the holiday season. , Now, BellasDress.com ... wedding gowns here at discount prices. The business hopes ... its website. , “All our elegant products ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 When head lice ... themselves in a frenzy to get rid of it while ... families in Coral Gables now have the solution right in ... salon clinic location, Lice Troopers provides full spectrum head lice ... Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, ...
(Date:12/25/2014)... 2014 (HealthDay News) -- The risk of burns from ... you need to be extra cautious, an expert says. ... a significant increase in patients coming in with burns," ... County Volunteer Firefighters Burn Center of Stony Brook University ... full of joy, but if not careful, could quickly ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... could be closing in on a "fountain of youth" drug ... health of older adults, a new study suggests. Seniors ... a drug that targets a genetic signaling pathway linked to ... report. The experimental medication, a version of ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers how this ... The old saying goes, “A picture says a thousand words.” ... describe a single image, because each picture holds a unique ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... Calif., March 20 Poniard Pharmaceuticals, Inc. (Nasdaq: ... on oncology, today announced that it will concentrate ... development of its late-stage oncology candidate, picoplatin. As ... preclinical research operations and reduced its workforce by ...
... Qutenza(TM) Receives Positive Committee Recommendation in European ... approval of Qutenza(TM) (formerly NGX-4010) for treatment ... either alone or in combination with other ... for review by U.S. FDA for PHNUpcoming ...
... March 20 Nuvilex, Inc. (OTC Bulletin Board: NVLX), formerly ... for the live conference call held on March 19, 2009 ... March 19, 2009 at 7:30 PM ET to March 26, ... 1-877-660-6853 (U.S.) and 1-201-612-7415 (international). To listen to the ...
... A campaign which will reduce mortality in patients with ... coalition which includes the ESC Working Group on Acute ... Interventions (EAPCI). "Stent 4 Life" is a project designed ... percutaneous coronary interventions (PCI, with balloon angioplasty and stent) ...
... leading private equity investment fund ("JLL"), and PharmaNet Development ... (Nasdaq: PDGI ) ("PharmaNet"), today announced the ... Holdings, LLC ("Parent"), through its wholly-owned subsidiary, PDGI Acquisition ... common stock of PharmaNet. Parent and Purchaser are ...
... to work, maybe you can walk at work ... 3 is National Walk to Work Day. ... Human Services, the sixth-annual event encourages Americans to ... http://www.newscom.com/cgi-bin/prnh/20090320/DE86407 )The reason is clear: According to ...
Cached Medicine News:Health News:Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization 2Health News:Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization 3Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 2Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 3Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 4Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 5Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 6Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 7Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 8Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 9Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 10Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 11Health News:Nuvilex Provides Conference Call Replay Information 2Health News:'Stent 4 Life': A campaign is launched to increase the use of primary PCI in acute coronary patients 2Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 2Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 3Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 4Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 5Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 6Health News:JLL Partners Announces Acceptance for Payment of Shares Tendered in PharmaNet Tender Offer and Commencement of Subsequent Offering Period 7Health News:National Walk to Work Day is April 3 2Health News:National Walk to Work Day is April 3 3
CVC 223 is an assayed quality control material used for confirming the calibration and linearity of CO-Oximeter instrumentation....
... control material used for monitoring the performance of ... for specific use on Bayer analyzers that measure ... 270) and the AVOX Systems CO-Oximeters (4000 and ... the IRMA TRUpoint. CC 527 is available in ...
RNA1c Control is an assayed quality control material used for monitoring the performance of Bayer DCA Analyzers that measure Hemoglobin A1c. It may be used on DCA 2000 and 2000+ analyzers....
... is a reagent and probe system used ... high throughput plate based system is a ... a unique approach for RNA detection and ... branched DNA (bDNA) technology. Branched DNA allows ...
Medicine Products: